TScan Therapeutics to Participate in the Guggenheim 2nd Annual Healthcare Innovation Conference Life Science Investing
Palvella Therapeutics Announces New QTORIN Product Candidate, QTORIN Pitavastatin, for the Treatment of Disseminated Superficial Actinic Porokeratosis , a Rare, Chronic, and Pre-Cancerous Genetic Skin Disease with No FDA-Approved Therapies Life Science Investing
Driven by Strong Demand, ImmunityBio Reports 467% Year-to-Date Unit Growth and $75 Million in Sales Year-to-Date, Up 434% from Q3 2024 Life Science Investing
Tenaya Therapeutics Announces New Clinical Data for TN-201 Gene Therapy will be Featured in Late-Breaking Presentation at the American Heart Association Scientific Sessions 2025 Life Science Investing
Exelixis Announces Third Quarter 2025 Financial Results and Provides Corporate Update Life Science Investing
